Search the webpage

Category: Glaucoma

Experimentica Ltd. offers a validated human trabecular meshwork cells for a variety of custom in vitro projects targeted at the trabecular meshwork.

SUMMARY

Species

Human

In vitro insult

TBD

Format

96-well plate

Read-outs

Custom, e.g. actin fiber length, focal adhesions

Please contact us, if you would like to receive more information: info@experimentica.com

IMAGES

Representative examples from primary human trabecular meshwork  cells

Effect of the rho kinase inhibitor netarsudil on actin fiber arrangement in primary human trabecular meshwork cells. Netarsudil (1.2 µM) results in a significant reduction of actin fiber length as assessed by labeling with fluorescently-labelled phalloidin (Actin GreenTM 488 ReadyProbesTM, Thermo Fisher).

Effect of the rho kinase inhibitor netarsudil on focal adhesions in primary human trabecular meshwork cells. Netarsudil (1.2 µM) results in a significant reduction in the number of focal adhesions, as quantified using anti-paxillin antibody (clone 5H11, EMD Millipore).

SELECTED PUBLICATIONS

REFERENCES

  • Lin, C.-W. W. et al. Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma. J Ocul Pharmacol Ther 34, 40–51 (2018).

Leave a Comment

LATEST NEWS

Experimentica at BioJapan 2018

News
Experimentica Ltd. exhibits at BioJapan2018 partnering event in Pacifico Yokohama, Japan, on October 10 – October 12 ... Read More

Meet Experimentica Ltd. team at EVER 2018

News
Visit our booth to explore our state-of-the-art capabilities in preclinical research and our posters on diabetic retinopathy, glaucoma, dry and ... Read More

Subscribe to Our Newsletter!

We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers too!